Voyager Therapeutics (VYGR) Consolidated Net Income (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Consolidated Net Income data on file, last reported at -$27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 9.94% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$116.6 million (down 38.52% YoY), and the FY2025 full-year result was -$119.7 million, down 85.58% from the prior year.
• Consolidated Net Income fell to -$27.9 million in Q1 2026, from -$27.4 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $124.0 million in Q1 2023 to a low of -$34.0 million in Q4 2024.
• A 5-year average of -$7.3 million and a median of -$22.2 million in 2023 frame the typical range for Consolidated Net Income.
• Peak annual rise in Consolidated Net Income reached 681.85% in 2023, while the deepest fall reached 246.96% in 2023.
• Tracing VYGR's Consolidated Net Income over 5 years: stood at -$23.6 million in 2022, then surged by 344.34% to $57.7 million in 2023, then sank by 158.93% to -$34.0 million in 2024, then advanced by 19.33% to -$27.4 million in 2025, then slipped by 1.86% to -$27.9 million in 2026.
• Business Quant data shows VYGR's Consolidated Net Income at -$27.9 million in Q1 2026, -$27.4 million in Q4 2025, and -$27.9 million in Q3 2025.